Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Trial details
- Registry ID
- NCT03623321
- Phase
- Phase 3
The FDA approved Pimavanserin (Nuplazid) on 29 Apr 2016.
Drug identity checked against registry records
Also recorded as Nuplazid
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03623321 | ACAD | Phase 3 | Completed | 2023-05-05Actual |
| A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052 | ACAD | Phase 3 | Completed | 2022-05-06Actual |
| Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderNCT05523895 | ACAD | Phase 2, Phase 3 | Completed | 2024-09-27Actual |
| Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderNCT05555615 | ACAD | Phase 2, Phase 3 | Terminated | 2025-02-14Actual |
| Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 | ACAD | Phase 3 | Terminated | 2024-04-30Actual |
| Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982 | ACAD | Phase 3 | Completed | 2024-01-25Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2016-04-29Day | Pimavanserin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA207318", "applicant_as_listed_by_fda": "ACADIA PHARMS INC", "brand_names": ["NUPLAZID"], "active_ingredients": ["PIMAVANSERIN TARTRATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160429", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |